Full Text Journal Articles by
Author Jean Christophe Boyer

Advertisement

Find full text journal articles






Model-based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer.

Alicja Puszkiel, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, Caroline Delmas, Florence Dalenc, Marc Debled, Laurence Venat-Bouvet, William Jacot, Nadine Dohollou, Chantal Bernard-Marty, Hortense Laharie-Mineur, Thomas Filleron, Henri Roché, Etienne Chatelut, Fabienne Thomas, Melanie White-Koning,

Variations in clinical response to tamoxifen (TAM) may be related to polymorphic cytochromes P450 (CYPs) involved in forming its active metabolite endoxifen (ENDO). We developed a population pharmacokinetic (popPK) model for tamoxifen and six metabolites to determine clinically relevant factors of ENDO exposure. Concentration-time data for TAM and six metabolites ... Read more >>

Clin Pharmacol Ther (Clinical pharmacology and therapeutics)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Looking for Root Hairs to Overcome Poor Soils.

Thanyakorn Rongsawat, Jean-Benoît Peltier, Jean-Christophe Boyer, Anne-Aliénor Véry, Hervé Sentenac,

Breeding new cultivars allowing reduced fertilization and irrigation is a major challenge. International efforts towards this goal focus on noninvasive methodologies, platforms for high-throughput phenotyping of large plant populations, and quantitative description of root traits as predictors of crop performance in environments with limited water and nutrient availability. However, these ... Read more >>

Trends Plant Sci (Trends in plant science)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

[Pharmacogenetics for patient care in France: A discipline that evolves!]

Chantal Barin-Le Guellec, Nicolas Picard, Hugo Alarcan, Melody Barreau, Laurent Becquemont, Sylvie Quaranta, Jean-Christophe Boyer, Marie-Anne Loriot, ,

Pharmacogenetics, which concepts are known for a long time, is entering a new period at least as far as its practical applications for patients are concerned. In recent years there have been more and more initiatives to promote widespread dissemination, and health authorities are increasingly incorporating these concepts into drug ... Read more >>

Therapie (Therapie)
[2019, :]

Cited: 0 times

View full text PDF listing >>



[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

Marie-Anne Loriot, Fadil Masskouri, Paolo Carni, Karine Le Malicot, Jean-François Seitz, Pierre Michel, Jean-Louis Legoux, Olivier Bouché, Thierry André, Roger Faroux, Suzette Delaloge, David Malka, Joel Guigay, Juliette Thariat, Fabienne Thomas, Chantal Barin-Le-Guellec, Joseph Ciccolini, Jean-Christophe Boyer, Marie-Christine Étienne-Grimaldi,

Dihydropyrimidine dehydrogenase (DPD) deficiency is the main cause of early severe toxicities induced by fluoropyrimidines (FP). The French Group of Clinical Oncopharmacology (GPCO)-Unicancer and the French Pharmacogenetics Network (RNPGx) initiated two surveys, one addressed to oncologists, the other to biologists, in order to evaluate routine practices regarding DPD deficiency screening ... Read more >>

Bull Cancer (Bulletin du cancer)
[2019, 106(9):759-775]

Cited: 0 times

View full text PDF listing >>



Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study.

Alicja Puszkiel, Cécile Arellano, Christelle Vachoux, Alexandre Evrard, Valérie Le Morvan, Jean-Christophe Boyer, Jacques Robert, Caroline Delmas, Florence Dalenc, Marc Debled, Laurence Venat-Bouvet, William Jacot, Etienne Suc, Isabelle Sillet-Bach, Thomas Filleron, Henri Roché, Etienne Chatelut, Melanie White-Koning, Fabienne Thomas,

In addition to the effect of cytochrome P450 (CYP) 2D6 genetic polymorphisms, the metabolism of tamoxifen may be impacted by other factors with possible consequences on therapeutic outcome (efficacy and toxicity). This analysis focused on the pharmacokinetic (PK)-pharmacogenetic evaluation of tamoxifen in 730 patients with adjuvant breast cancer included in ... Read more >>

Clin. Pharmacol. Ther. (Clinical pharmacology and therapeutics)
[2019, 106(3):585-595]

Cited: 1 time

View full text PDF listing >>



How can we best monitor 5-FU administration to maximize benefit to risk ratio?

Françoise Goirand, Florian Lemaitre, Manon Launay, Camille Tron, Etienne Chatelut, Jean-Christophe Boyer, Marc Bardou, Antonin Schmitt,

INTRODUCTION:5-Fluorouracil (5-FU) is currently used as a chemotherapy in several cancers such as head-and-neck (H&N) and colorectal cancers. 5-FU dosing is traditionally based on body surface area (BSA), but this strategy is usually associated with severe toxicities. 5-FU is mainly catabolized by dihydropyrimidine dehydrogenase (DPD), and 5-FU dosage adaptation according ... Read more >>

Expert Opin Drug Metab Toxicol (Expert opinion on drug metabolism & toxicology)
[2018, 14(12):1303-1313]

Cited: 0 times

View full text PDF listing >>



[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].

Florian Lemaitre, Françoise Goirand, Manon Launay, Etienne Chatelut, Jean-Christophe Boyer, Alexandre Evrard, Marie-Noelle Paludetto, Romain Guilhaumou, Joseph Ciccolini, Antonin Schmitt,

Despite being 60-years old now, 5-FU remains the backbone of numerous regimen to treat a variety of solid tumors such as breast, head-and-neck and digestive cancers either in neo-adjuvant, adjuvant or metastatic settings. Standard 5-FU usually claims 15-40% of severe toxicities and up to 1% of toxic-death. Numerous studies show ... Read more >>

Bull Cancer (Bulletin du cancer)
[2018, 105(9):790-803]

Cited: 0 times

View full text PDF listing >>



[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].

Marie-Anne Loriot, Joseph Ciccolini, Fabienne Thomas, Chantal Barin-Le-Guellec, Bernard Royer, Gérard Milano, Nicolas Picard, Laurent Becquemont, Céline Verstuyft, Céline Narjoz, Antonin Schmitt, Christine Bobin-Dubigeon, Alexandre Harle, Angelo Paci, Vianney Poinsignon, Sylvie Quaranta, Alexandre Evrard, Benjamin Hennart, Franck Broly, Xavier Fonrose, Claire Lafay-Chebassier, Anne-Sophie Wozny, Fadil Masskouri, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi,

Fluoropyrimidines (FU) are still the most prescribed anticancer drugs for the treatment of solid cancers. However, fluoropyrimidines cause severe toxicities in 10 to 40% of patients and toxic deaths in 0.2 to 0.8% of patients, resulting in a real public health problem. The main origin of FU-related toxicities is a ... Read more >>

Bull Cancer (Bulletin du cancer)
[2018, 105(4):397-407]

Cited: 7 times

View full text PDF listing >>



New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Christophe Beroud, Litaty Mbatchi, André van Kuilenburg, Christine Bobin-Dubigeon, Fabienne Thomas, Etienne Chatelut, Jean-Louis Merlin, Frédéric Pinguet, Christophe Ferrand, Judith Meijer, Alexandre Evrard, Laurence Llorca, Gilles Romieu, Philippe Follana, Thomas Bachelot, Loic Chaigneau, Xavier Pivot, Véronique Dieras, Rémy Largillier, Mireille Mousseau, Anthony Goncalves, Henri Roché, Jacques Bonneterre, Véronique Servent, Nadine Dohollou, Yann Château, Emmanuel Chamorey, Jean-Pierre Desvignes, David Salgado, Jean-Marc Ferrero, Gérard Milano,

Deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants ... Read more >>

PLoS One (PloS one)
[2017, 12(5):e0175998]

Cited: 10 times

View full text PDF listing >>



Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.

Marie-Christine Etienne-Grimaldi, Chantal Barin Le Guellec, Jean-Christophe Boyer, Etienne Chatelut, Alexandre Evrard, Marie-Anne Loriot, Angelo Paci, Bernard Royer, Fabienne Thomas, Joseph Ciccolini,

Semin. Oncol. (Seminars in oncology)
[2017, 44(2):159-160]

Cited: 0 times

View full text PDF listing >>



Cancer genomics guide clinical practice in personalized medicine.

Jacqueline Lehmann-Che, Brigitte Poirot, Jean-Christophe Boyer, Alexandre Evrard,

Targeted therapies have revolutionized the treatment of many cancers. Widely developed over the last decade, this new concept of precision medicine relies on the use of genomic technologies to analyze tumor samples in order to identify actionable targets and biomarkers of resistance. The goal is to optimize treatment by identifying ... Read more >>

Therapie (Therapie)
[2017, 72(4):439-451]

Cited: 2 times

View full text PDF listing >>



Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).

Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Chantal Barin-Le Guellec, Fabienne Thomas, Marie-Anne Loriot, ,

More than 50 laboratories offer pharmacogenetic testing in France. These tests are restricted to a limited number of indications: prevention of serious adverse drug reactions; choice of most appropriate therapeutic option; dose adjustment for a specific drug. A very small proportion of these tests are mentioned in drug information labeling ... Read more >>

Therapie (Therapie)
[2017, 72(2):185-192]

Cited: 1 time

View full text PDF listing >>



La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision.

Jacqueline Lehmann-Che, Brigitte Poirot, Jean Christophe Boyer, Alexandre Evrard,

Therapie (Therapie)
[2017, 72(2):217-230]

Cited: 0 times

View full text PDF listing >>



Traitements personnalisés grâce à la pharmacogénétique : niveaux de preuve et de recommandations du Réseau national de pharmacogénétique (RNPGx).

Nicolas Picard, Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Chantal Barin-Le Guellec, Fabienne Thomas, Marie-Anne Loriot, ,

Therapie (Therapie)
[2017, 72(2):175-183]

Cited: 1 time

View full text PDF listing >>



Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients.

Litaty Céphanoée Mbatchi, Jacques Robert, Marc Ychou, Jean-Christophe Boyer, Maguy Del Rio, Matthieu Gassiot, Fabienne Thomas, Nicole Tubiana, Alexandre Evrard,

Nuclear receptors PXR (pregnane X receptor, NR1I2) and CAR (constitutive androstane receptor, NR1I3) are key regulators of irinotecan metabolism, and ligand-dependent modulation of their activity leads to significant drug-drug interactions. Because genetic polymorphisms can also affect the activity of these xenobiotic-sensing receptors, we hypothesized that they could contribute to the ... Read more >>

Clin Pharmacokinet (Clinical pharmacokinetics)
[2016, 55(9):1145-1157]

Cited: 7 times

View full text PDF listing >>



Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.

Fanny Grillet, Elsa Bayet, Olivia Villeronce, Luke Zappia, Ebba Louise Lagerqvist, Sebastian Lunke, Emmanuelle Charafe-Jauffret, Kym Pham, Christina Molck, Nathalie Rolland, Jean François Bourgaux, Michel Prudhomme, Claire Philippe, Sophie Bravo, Jean Christophe Boyer, Lucile Canterel-Thouennon, Graham Roy Taylor, Arthur Hsu, Jean Marc Pascussi, Frédéric Hollande, Julie Pannequin,

Although counting of circulating tumour cells (CTC) has attracted a broad interest as potential markers of tumour progression and treatment response, the lack of functional characterisation of these cells had become a bottleneck in taking these observations to the clinic. Our objective was to culture these cells in order to ... Read more >>

Gut (Gut)
[2017, 66(10):1802-1810]

Cited: 45 times

View full text PDF listing >>



Nod Factor Effects on Root Hair-Specific Transcriptome of Medicago truncatula: Focus on Plasma Membrane Transport Systems and Reactive Oxygen Species Networks.

Isabelle Damiani, Alice Drain, Marjorie Guichard, Sandrine Balzergue, Alexandre Boscari, Jean-Christophe Boyer, Véronique Brunaud, Sylvain Cottaz, Corinne Rancurel, Martine Da Rocha, Cécile Fizames, Sébastien Fort, Isabelle Gaillard, Vincent Maillol, Etienne G J Danchin, Hatem Rouached, Eric Samain, Yan-Hua Su, Julien Thouin, Bruno Touraine, Alain Puppo, Jean-Marie Frachisse, Nicolas Pauly, Hervé Sentenac,

Root hairs are involved in water and nutrient uptake, and thereby in plant autotrophy. In legumes, they also play a crucial role in establishment of rhizobial symbiosis. To obtain a holistic view of Medicago truncatula genes expressed in root hairs and of their regulation during the first hours of the ... Read more >>

(Frontiers in plant science)
[2016, 7:794]

Cited: 7 times

View full text PDF listing >>



Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

Litaty Céphanoée Mbatchi, Antonin Schmitt, Fabienne Thomas, Yoann Cazaubon, Jacques Robert, Serge Lumbroso, Jean-Paul Brouillet, Philippe Pourquier, Etienne Chatelut, Jean-Christophe Boyer, Alexandre Evrard,

The goal of our study was to assess the impact of patients' genetic background on their sensitivity to carboplatin/paclitaxel hematotoxicity.Parameters describing sensitivity to neutropenia and to thrombocytopenia of 201 patients were extracted from a previous pharmacokinetic/pharmacodynamics analysis, in order to assess their association with 52 candidates SNPs in 18 genes.Carriers ... Read more >>

Pharmacogenomics (Pharmacogenomics)
[2015, 16(13):1439-1450]

Cited: 8 times

View full text PDF listing >>



The Arabidopsis root stele transporter NPF2.3 contributes to nitrate translocation to shoots under salt stress.

Christelle Taochy, Isabelle Gaillard, Emilie Ipotesi, Ronald Oomen, Nathalie Leonhardt, Sabine Zimmermann, Jean-Benoît Peltier, Wojciech Szponarski, Thierry Simonneau, Hervé Sentenac, Rémy Gibrat, Jean-Christophe Boyer,

In most plants, NO(3)(-) constitutes the major source of nitrogen, and its assimilation into amino acids is mainly achieved in shoots. Furthermore, recent reports have revealed that reduction of NO(3)(-) translocation from roots to shoots is involved in plant acclimation to abiotic stress. NPF2.3, a member of the NAXT (nitrate ... Read more >>

Plant J. (The Plant journal : for cell and molecular biology)
[2015, 83(3):466-479]

Cited: 35 times

View full text PDF listing >>



UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.

Marie-Christine Etienne-Grimaldi, Jean-Christophe Boyer, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Céline Narjoz, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec, , ,

Irinotecan is a major drug in the treatment of advanced colorectal cancer. Its active form is the SN38 metabolite, which is cleared by the biliary route after glucuronidation by uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). UGT1A1 activity exhibits a wide intersubject variability, in part related to UGT1A1 gene polymorphisms. The present review ... Read more >>

Fundam Clin Pharmacol (Fundamental & clinical pharmacology)
[2015, 29(3):219-237]

Cited: 36 times

View full text PDF listing >>



[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].

Jean-Christophe Boyer, Marie-Christine Etienne-Grimaldi, Fabienne Thomas, Sylvie Quaranta, Nicolas Picard, Marie-Anne Loriot, Delphine Poncet, Marie-Claude Gagnieu, Cécile Ged, Franck Broly, Valérie Le Morvan, Régis Bouquié, Marie-Pierre Gaub, Laurent Philibert, François Ghiringhelli, Chantal Le Guellec,

Irinotecan is a cytotoxic agent administered by IV infusion in the treatment of advanced colorectal cancer. Its anticancer activity results from its bioactivation into SN-38 metabolite, which is cleared through glucuronidation by the hepatic enzyme uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). In the general population, there is wide inter-subject variability in UGT1A1 ... Read more >>

Bull Cancer (Bulletin du cancer)
[2014, 101(6):533-553]

Cited: 5 times

View full text PDF listing >>



Unilateral subarachnoid and intravitreous FLAIR hyperintensities after gadolinium-enhanced MRI.

Dimitri Renard, Christian Moesch, Jean Christophe Boyer, Cornelia Freitag, Eric Thouvenot,

Acta Neurol Belg (Acta neurologica Belgica)
[2015, 115(1):89-90]

Cited: 0 times

View full text PDF listing >>



A unified nomenclature of NITRATE TRANSPORTER 1/PEPTIDE TRANSPORTER family members in plants.

Sophie Léran, Kranthi Varala, Jean-Christophe Boyer, Maurizio Chiurazzi, Nigel Crawford, Françoise Daniel-Vedele, Laure David, Rebecca Dickstein, Emilio Fernandez, Brian Forde, Walter Gassmann, Dietmar Geiger, Alain Gojon, Ji-Ming Gong, Barbara A Halkier, Jeanne M Harris, Rainer Hedrich, Anis M Limami, Doris Rentsch, Mitsunori Seo, Yi-Fang Tsay, Mingyong Zhang, Gloria Coruzzi, Benoît Lacombe,

Members of the plant NITRATE TRANSPORTER 1/PEPTIDE TRANSPORTER (NRT1/PTR) family display protein sequence homology with the SLC15/PepT/PTR/POT family of peptide transporters in animals. In comparison to their animal and bacterial counterparts, these plant proteins transport a wide variety of substrates: nitrate, peptides, amino acids, dicarboxylates, glucosinolates, IAA, and ABA. The ... Read more >>

Trends Plant Sci. (Trends in plant science)
[2014, 19(1):5-9]

Cited: 178 times

View full text PDF listing >>



Lexical fields of predictive and personalized medicine.

Thierry Mathieu, Laurent Bermont, Jean-Christophe Boyer, Céline Versuyft, Alexandre Evrard, Isabelle Cuvelier, Remy Couderc, Katell Peoc'h, ,

With human genome mapping, the omics revolution and the empowering sequencing technologies developed at the turn of the century, the new goals in medicine are to switch from population medicine to individualized therapies, not only to cure diseases but also to prevent them. The purpose of this review by the ... Read more >>

Drug Metabol Drug Interact (Drug metabolism and drug interactions)
[2013, 28(2):125-132]

Cited: 0 times

View full text PDF listing >>



Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Hélène Blons, Etienne Rouleau, Nathanaël Charrier, Gilles Chatellier, Jean-François Côté, Jean-Christophe Pages, Florence de Fraipont, Jean-Christophe Boyer, Jean Philippe Merlio, Alain Morel, Marie-Claude Gorisse, Patricia de Cremoux, Karen Leroy, Gérard Milano, L'houcine Ouafik, Jean-Louis Merlin, Delphine Le Corre, Pascaline Aucouturier, Jean-Christophe Sabourin, Frédérique Nowak, Thierry Frebourg, Jean-François Emile, Isabelle Durand-Zaleski, Pierre Laurent-Puig, ,

Rapid advances in the understanding of cancer biology have transformed drug development thus leading to the approval of targeted therapies and to the development of molecular tests to select patients that will respond to treatments. KRAS status has emerged as a negative predictor of clinical benefit from anti-EGFR antibodies in ... Read more >>

PLoS One (PloS one)
[2013, 8(7):e68945]

Cited: 11 times

View full text PDF listing >>



Advertisement

Disclaimer
1.1958 s